Dr. McGilvray studied medicine at McGill University, graduating in 1993. He entered the General Surgery training program at the University of Toronto that same year. During his residency, he undertook graduate studies in Dr. Ori Rotstein’s laboratory and obtained a PhD in Cell Biology. He became a Fellow of the Royal College of Physicians and Surgeons of Canada in 2001. After a clinical fellowship in Transplantation and Hepatobiliary Surgery at the Toronto General Hospital, he began his appointment at the University Health Network in 2003. He is currently an Associate Professor in the Department of Surgery at the University of Toronto.
- Diseases of the liver, particularly viral hepatitis
- Transplant immunology
- Hepatic ischemia/reperfusion injury
- Vascular reconstructive techniques for locally advanced liver and pancreas cancer
- Applicability of transplantation to oncology diagnoses
Normothermic Ex Vivo Liver Perfusion Using Steen Solution as Perfusate for Human Liver Transplantation-First North American Results.
Liver Transpl. 2016 Jun 24;
Treatment with Optifast® Reduces Hepatic Steatosis and Increases Candidacy Rates for Live Donor Liver Transplantation.
Liver Transpl. 2016 Jun 17;
Creating an animation-enhanced video library of hepato-pancreato-biliary and transplantation surgical procedures.
J Vis Commun Med. 2016 Jun 3;:1-6
PLoS One. 2016;11(5):e0151829
The extended toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.
Hepatology. 2016 May 14;
Am J Transplant. 2016 Apr 18;
J Virol. 2016 Mar 23;
J Control Release. 2016 Jan 13;
Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
J Viral Hepat. 2015 Dec 29;
Clin Transplant. 2015 Dec 24;
Scientist, Toronto General Hospital Research Institute (TGHRI)
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Surgery, Faculty of Medicine, University of Toronto